Randomized Double Blinded Study Evaluating CACICOL20 Efficiency Versus Placebo Corneal Chronic Ulcers Healing (UNICOL)

Randomized Multicentric Double Blinded Study Evaluating CACICOL20 Efficiency Versus Placebo Corneal Chronic Ulcers Healing

CACICOL20 is a biodegradable nanopolymer engineered to mimic glycosaminoglycans such as heparan sulfates. Applied to the corneal lesion, it replaces damaged heparan sulfates in the matrix scaffold. CACICOL20 binds to matrix proteins such as collagen and cytokines or endogenous growth factors of the cellular microenvironment. CACICOL20 provides a protective function and restores the matrix architecture. This produces a suitable spatial environment for cells to respond properly to the cascade of signals needed for tissue regeneration to resume.

The ophthalmic solution, CACICOL20, used for corneal ulcers is very well tolerated both locally and generally, as proved by a pilot study which as been conducted at the "Hôpital des XV-XX" in Paris (France). It reduces the pain significantly and increases corneal ulcer healing (all ulcers treated were resistant to all other usual therapies).

Therefore, the accuracy of a Randomized multicentric double blinded study to evaluate the efficacy of CACICOL20 versus placebo for chronic corneal ulcer healing has been shown and will begin mid-may 2010. In this study, CACICOL20 will be applied every 2 or 4 days for 3 months.

The aim of the study is a double blinded comparison of complete chronic corneal ulcers healing rate within 3 months in 3 groups of patient double blinded randomized between CACICOL20 instillations distribution and physiological salt solution instillations distribution.

The main judgment criteria is healing rate within 3 months defined as corneal ulcer complete closure.

Study Overview

• Status: Completed
• Conditions: Corneal Ulcer
• Intervention / Treatment: Device: CACICOL20; Device: Placebo

• Study Type: Interventional
• Enrollment (Actual): 139
• Phase: Not Applicable

Contacts and Locations

Study Locations

• France
  • Amiens, France, 80054
    • Centre Hospitalier Universitaire Amiens
  • Angers, France, 49933
    • CHU Angers
  • Bobigny, France, 93009
    • Hopital Avicennes
  • Boulogne Billancourt, France, 92100
    • Centre Hospitalier Ambroise Paré
  • Clermont Ferrand, France, 63003
    • Hôpital Gabriel Montpied - CHU Clermont Ferrand
  • Dijon, France, 21079
    • Centre Hospitalier Universitaire de Dijon
  • Le Kremlin-bicetre, France, 94275
    • Hôpital Bicêtre
  • Lille, France, 59037
    • CHRU Lille Hôpital Huriez
  • Limoges, France, 87042
    • CHU Limoges, Hôpital Dupuytren
  • Lyon, France, 69003
    • CHU LYON, Hôpital Edouard Herriot
  • Marseille, France, 13385
    • AP-HM Hopital de la Timone
  • Nantes, France, 44093
    • Centre Hospitalier Universitaire de Nantes
  • Paris, France, 75019
    • Fondation Ophtalmologique Adolphe de Rothschild
  • Paris, France, 75181
    • AP-HP Hôpital Hôtel-Dieu
  • Paris, France, 75571
    • Centre Hospitalier des Quinze Vingt
  • Paris, France, 75877
    • Hôpital Bichat - Claude-Bernard
  • Rouen, France, 76031
    • CHU Hôpitaux de Rouen
  • Saint Jean d'Angély, France, 17415
    • CH Saint Louis, Saint Jean d'Angély
  • Saint-Etienne, France, 42055
    • Centre Hospitalier Universitaire de Saint-Etiennne
  • Strasbourg, France, 67091
    • Hôpitaux Universitaires de Strasbourg
  • Tours, France, 37044
    • Centre Hospitalier Universitaire de Tours

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 75 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Patients with non-infectious, corneal chronic ulcer, painful or not ,whose depth does not exceed the superficial stroma.
• Resistance of corneal pathology to standard treatment: eye drops to promote healing, tear substitutes, anti-inflammatory drugs, cyclosporin.
• Patients previously treated for the corneal pathology, assessed ineffective or Insufficiently effective by the investigator
• Patients using wetting gel or eye drops without conservator during the inclusion
• Anti-inflammatory local treatments must be stopped for at least 8 days.
• No contact lenses or lenses must be removed for at least 8 days.
• Age of inclusion ≥ 18 years.
• Written and signed informed consent from patient.
• Realization of a preliminary medical examination.
• Covers by social insurance

Exclusion Criteria:

• Ulcers deeper than the superficial stroma, perforated ulcers or pre-perforated
• Corneal abscess
• Infectious and progressive ulcerative keratitis
• Patients receiving anti-inflammatory eye drops or steroid with cyclosporine treatment (in this case, possibility of inclusion in the clinical protocol after a Case "wash-out of 8 days)
• Patients on long-term eye drops containing preservatives and can not be stopped or replaced by an equivalent without preservatives
• Patients on systemic anti-inflammatory, anti-allergic, psychotropic or antibiotics therapies, modified since less than 10 days or likely to be on short-term
• Wearing contact lenses if patient has not been stopped at least eight days before the start of the protocol
• ocular surgery within the last 3 months
• patient already included in another clinical trial with an investigational product
• Pregnant patients or breastfeeding
• Person under a legal protection measure, under guardianship
• Unable to follow up medical examinations for geographical, social or psychological reasons
• Not cover by social insurance.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Quadruple

Number of Arms

3

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: CACICOL20; Arm that receives CACICOL20 treatment each 2 days for 3 months/until closure of the ulcer	Device: CACICOL20; CACICOL20 is a solution of dextran & poly(carboxymethylglucose sulphate)in physiological salt serum. CACICOL20 is presented in 0.33 mL strip. One drop is instilled at each application to impregnate cornea.
Placebo Comparator: Placebo; The placebo is applicated each 2 days on patient cornea for 3 months/ until ulcer closure.	Device: Placebo; It is the placebo of CACICOL20, containing dextran in physiological serum salt. It is presented, like CACICOL20, in a 0.33 mL strip. One drop is delivered at each application.
Experimental: CACICOL20 and Placebo; Patient applies the treatment each 2 days for 3 months or until closure of the ulcer. This treatment is alternatively CACICOL20 or Placebo : so the patient receives CACICOL20 each 4 days. CACICOL20 and placebo strips are strictly similar and cannot be identified.	Device: CACICOL20; CACICOL20 is a solution of dextran & poly(carboxymethylglucose sulphate)in physiological salt serum. CACICOL20 is presented in 0.33 mL strip. One drop is instilled at each application to impregnate cornea.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Healing rate	The main judgment criteria is healing rate within 3 months defined as corneal ulcer complete closure.	Within 1 months

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Healing rate	Complete Healing rate of the ulcer at 1 and 2 months defined as corneal ulcer complete closure, the evaluation of the pain with visual pain scale and evaluation of the quotation of analgesic treatments used by the patient.	2 and 3 months
Visual pain scale	Complete Healing rate of the ulcer at 1 and 2 months defined as corneal ulcer complete closure, the evaluation of the pain with visual pain scale and evaluation of the quotation of analgesic treatments used by the patient.	1, 2 and 3 months
Associated treatments quotation	Quotation of analgesic treatments used and assessment of the effects of lubricant eye drops on the patient.	1, 2 and 3 months

Collaborators and Investigators

• Sponsor: Organ, Tissue, Regeneration, Repair and Replacement
• Collaborators: Assistance Publique - Hôpitaux de Paris
• Investigators: Principal Investigator: Christophe Baudouin, MD, XV- XX Hospital - Paris

Study record dates

Study Major Dates

• Study Start: April 1, 2010
• Primary Completion (Actual): June 1, 2014
• Study Completion (Actual): June 1, 2014

Study Registration Dates

• First Submitted: September 3, 2010
• First Submitted That Met QC Criteria: November 16, 2010
• First Posted (Estimate): November 17, 2010

Study Record Updates

• Last Update Posted (Estimate): May 5, 2016
• Last Update Submitted That Met QC Criteria: May 4, 2016
• Last Verified: May 1, 2016

More Information

Terms related to this study

• Keywords: CACICOL20
• Additional Relevant MeSH Terms: Pathologic Processes; Infections; Eye Diseases; Keratitis; Corneal Diseases; Eye Infections; Ulcer; Corneal Ulcer
• Other Study ID Numbers: CT08L06UC

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No